As we move into Q2, the team at Bluewell Peptides is excited to share several important developments that reflect our long-term commitment to supporting the research community with high-quality compounds, transparent quality control, and reliable supply.
Over the past months we have been working behind the scenes to expand our catalogue, improve our infrastructure, and strengthen the quality standards that define the Bluewell brand.
This update outlines what researchers can expect in the coming months.
New Research Peptides Being Added to the Catalogue
One of the most exciting developments heading into Q2 is the expansion of our peptide catalogue. These additions are currently listed in our Coming Soon section and will be available as stock arrives.
Upcoming additions include:
• AICAR 50mg
• BPC-157 + TB-5OO Blend 20mg
• Dermorphin 5mg
• FTTP Adipotide 5mg
• Hexarelin Acetate 5mg
• Pinealon 20mg
• PNC-27 5mg
• Thymalin 10mg
• VIP 10mg
Each compound will continue to follow the same Bluewell quality framework, including:
- High purity verification through HPLC testing
- Full Certificates of Analysis (COAs)
- Proper lyophilised storage conditions
- Transparent batch tracking
These peptides represent areas of growing interest in scientific research, including cellular signalling, neuropeptide pathways, metabolic regulation, and peptide-targeted biological systems.
Our goal is to continue expanding the catalogue with compounds that are relevant to modern laboratory research, while maintaining strict quality standards.
Expansion to a New Shipping and Fulfilment Facility
Another major milestone for Bluewell this quarter is our move to a new dedicated shipping and fulfilment facility.
As demand has grown, it became clear that expanding our operational capacity was the next step in maintaining the reliability our research partners expect.
During the week leading up to the transition, some compounds may temporarily show as out of stock while new batches are being set up and transferred into our new facility. These products will not be visible on the website until the setup process is complete, with normal availability expected to return by the 20th.
This short transition period allows us to organise new inventory batches, implement improved storage systems, and ensure all products are fully documented and quality checked before being released back into the catalogue.
The new facility provides:
• Significantly larger storage capacity
• More dedicated temperature-controlled environments
• Faster order processing and dispatch workflows
• More efficient inventory management systems
This upgrade ensures that Bluewell can continue delivering consistent and reliable shipping across the UK and internationally, even as our catalogue grows.
Growing the Bluewell Team
Alongside the facility expansion, we are also expanding our team.
Bluewell is bringing in additional staff, operational specialists, and scientific consultants to support our continued growth and maintain the level of service our customers expect.
Our focus is not just growth for the sake of scale, but growth that allows us to maintain precision, reliability, and transparency in every aspect of the business.
This includes strengthening support for:
- Order processing
- quality control workflows
- research documentation
- customer support for laboratories and institutions
Upgraded Equipment and Quality Control Systems
Quality control has always been central to how Bluewell operates.
As part of our Q2 expansion, we have invested in new laboratory equipment and improved testing infrastructure designed to enhance the verification process for every batch we supply.
These upgrades allow us to maintain extremely high levels of confidence in the compounds we provide to the research community.
Introducing Additional Endotoxin Testing
While our peptides already undergo strict quality verification, we are introducing additional endotoxin testing protocols as part of our upgraded quality control framework.
It is important to clarify that our current peptides already meet stringent purity standards, and endotoxin contamination has not been identified as an issue in our testing.
However, implementing additional endotoxin screening allows us to provide an extra layer of reassurance and transparency for the laboratories and researchers who rely on Bluewell products.
Our philosophy is simple:
If there is a way to raise standards further, we will do it.
Raising the Standard for Research Suppliers
The peptide research space has grown rapidly in recent years, but quality standards across suppliers can vary widely.
At Bluewell Peptides, our goal is not just to participate in this industry, but to raise the bar for what researchers should expect from a supplier.
That means:
• Clear documentation
• verified purity
• transparent sourcing
• strong quality control
• reliable fulfilment
• ongoing improvements to testing and infrastructure
We believe the research community deserves suppliers who prioritise accuracy, integrity, and consistency.
Looking Ahead
Q2 marks an important step forward for Bluewell.
With a growing catalogue, expanded infrastructure, and strengthened quality systems, we are focused on building a platform that researchers can rely on long term.
The coming months will see:
• New peptides added to the catalogue
• Improved fulfilment capabilities
• stronger quality verification processes
• continued investment into the Bluewell research ecosystem
We are grateful to the researchers and laboratories who continue to support Bluewell as we grow.
Together, we look forward to pushing the standards of the research peptide industry in the right direction.
